General Information of Drug (ID: DM1D2O0)

Drug Name
KML-001 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
60356606
TTD Drug ID
DM1D2O0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Berberine DMC5Q8X N. A. N. A. Phase 4 [3]
GV1001 DMHULRK Pancreatic cancer 2C10 Phase 3 [4]
Imetelstat DMONWJ4 Myelodysplastic syndrome 2A37 Phase 2/3 [5]
VM1500A DM9YSSY Human immunodeficiency virus-1 infection 1C62 Phase 2/3 [6]
Dendritic cell vaccine DML4PMG Ovarian cancer 2C73 Phase 2 [7]
GRNVAC1 DMAHOEP Acute myeloid leukaemia 2A60 Phase 2 [8]
Vx-001 DMDKWA3 Breast cancer 2C60-2C65 Phase 2 [9]
CB-10-01 DM2IFYZ Melanoma 2C30 Phase 2 [10]
Epithalon DMWSGZU Ocular inflammation 9C61.24 Phase 1/2 [11]
OBP-301 DM9MF08 Breast cancer 2C60-2C65 Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Telomerase reverse transcriptase (TERT) TTUJFD0 TERT_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT01110226) Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies. U.S. National Institutes of Health.
2 National Cancer Institute Drug Dictionary (drug id 672554).
3 Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002 Mar;51(1):99-103.
4 Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006 Dec 4;95(11):1474-82.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida(?)) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms. J Enzyme Inhib Med Chem. 2021 Dec;36(1):1056-1060.
7 In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. J Immunotoxicol. 2009 Dec;6(4):243-8.
8 Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011 Jul;15(7):1433-42.
9 Clinical pipeline report, company report or official report of Vaxon-biotech.
10 Telomerase immunity from bench to bedside: round one. J Transl Med. 2007 Feb 26;5:12.
11 Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003 Jun;135(6):590-2.
12 Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92.